Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Outcomes of Acute Myeloid Leukemia patients undergoing hematopoietic stem cell transplantation with and without pre-existing heart failure: A national inpatient analysis

Abdulmalek Aljafari, Mohamed Elganainy, Adnan Humam Hajjar et al. Nov 03, 2025 pp. 2856-2856 10.1182/blood-2025-2856

Abstract Background: Hematopoietic stem cell transplantation (HSCT) offers curative potential for patients with acute myeloid leukemia (AML)...

First results of the methoglu Trial, a phase 1 Trial from the LOC network evaluating the reduction of the time interval between methotrexate perfusions combined with glucarpidase in relapsed primary CNS lymphomas

Caroline Houillier, Lisa Belin, Cécile Moluçon-Chabrot et al. Nov 03, 2025 pp. 1904-1904 10.1182/blood-2025-1904

Abstract Introduction High-dose methotrexate (hdMTX) is the key drug in primary central nervous system lymphoma (PCNSL)....

Transplant outcomes for children and adolescents with severe aplastic anemia comparing matched sibling donor and haploidentical transplant approaches.

Gerardo Lopez Hernandez, Haydee Salazar, Rosa Maria Nidesha Ramírez Uribe et al. Nov 03, 2025 pp. 7720-7720 10.1182/blood-2025-7720

Abstract Introduction Recent studies comparing matched sibling donor (MSD) and haploidentical donor with post-transplant cyclophosphamide (h...

TFH subsets in patients after allogenic transplant are dysregulated prior to chronic GVHD development

Isabel Sandner, Katharina Habenicht, Thomas Winkler et al. Nov 03, 2025 pp. 6023-6023 10.1182/blood-2025-6023

Abstract Background: Chronic graft-versus-host disease (cGvHD) remains a major cause of late morbidity and mortality after allogeneic hemato...

Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma

Sofie-Katrin Kadel, Alexander Leipold, Philipp Weis et al. Nov 03, 2025 pp. 5698-5698 10.1182/blood-2025-5698

Abstract Introduction: BCMA × CD3 bispecific antibodies such as teclistamab induce high response rates and durable remis...

Safety data from the non-transfusion-dependent dose-confirmation cohort: A phase 2a study of luspatercept in pediatric patients with β-thalassemia

Vip Viprakasit, Jianpei Fang, Khaled Musallam et al. Nov 03, 2025 pp. 1135-1135 10.1182/blood-2025-1135

Abstract Introduction: β-thalassemia is characterized by ineffective erythropoiesis leading to chronic anemia. Although patients with non-tr...

Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?

Maria Victoria del Rosal, Saoirse Bodnar, Tehilla Brander et al. Nov 03, 2025 pp. 2151-2151 10.1182/blood-2025-2151

Abstract Pathogenic germline variants (PGVs) are present in ~10 % of unselected multiple myeloma (MM) cases (Thibaud et al., Blood Cancer Di...

Uric acid - a potent antioxidant with protective and toxic affects on renal function

Robert Hagar, Shiran Chen, Sam Walters et al. Nov 03, 2025 pp. 1173-1173 10.1182/blood-2025-1173

Abstract Introduction Sickle cell disease (SCD) is a recessive blood disease affecting about 300,000 newborns every year...

Combining next-generation sequencing and optical genome mapping techniques to analyze genomic abnormalities in marginal zone lymphoma

Xixi Xiang, Bo Liu, Yang Hanshan et al. Nov 03, 2025 pp. 3535-3535 10.1182/blood-2025-3535

Abstract Introduction: Optical genome mapping (OGM) is a novel DNA-based technology enabling comprehensive genome-wide analysis of cytogenomi...

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Alyssa Kassouf, Rina Welkie, Yazeed Sawalha et al. Nov 03, 2025 pp. 4526-4526 10.1182/blood-2025-4526

Abstract Introduction: Chemotherapy-induced nausea and vomiting (CINV) remains an important side effect of chemotherapy for patients with cl...

Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing

Michael Slade, Mark Fiala, Julie Fortier et al. Nov 03, 2025 pp. 2218-2218 10.1182/blood-2025-2218

Abstract Introduction The International Myeloma Working Group (IMWG) recently published an updated high-risk (HR) definition for multiple my...

Evaluation of the therapeutic results of NHL-BFM-90 and R-CHOEP in HIV-associated burkitt's lymphoma

Arman Hovhannisyan, Galina Dudina, Maria Litvinenko et al. Nov 03, 2025 pp. 7209-7209 10.1182/blood-2025-7209

Abstract Introduction. Patients with HIV infection have a higher risk of developing malignant neoplasms, including aggressive lymphoprolifer...

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Alice Wang, Luca Paruzzo, Martina Bonomi et al. Nov 03, 2025 pp. 5337-5337 10.1182/blood-2025-5337

Abstract Background: CD19-directed CART cell (CART19) therapy is standard of care for relapsed/refractory large B-cell lymphomas (r/r LBCL),...

Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study

Thomas Cluzeau, Cécile Favreau, Maxence Bourgoin et al. Nov 03, 2025 pp. 5250-5250 10.1182/blood-2025-5250

Abstract Background Azacitidine (AZA) combined with venetoclax (VEN) is the standard of care for patients with acute myeloid leukemia (AML)...

Development of a CAR-NK therapy regulated by the KLRC1 locus as a new platform for selective control of acute myeloid leukaemia

Asunción Borrero Borrego, Sarah Sleiman, Nathan Welty et al. Nov 03, 2025 pp. 5907-5907 10.1182/blood-2025-5907

Abstract In the era of CAR-T cell therapies, growing efforts are underway to adapt these strategies to Acute Myeloid Leukaemia (AML). Natura...

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Salomon Manier, Noemi Puig, Xavier Leleu et al. Nov 03, 2025 pp. 2288-2288 10.1182/blood-2025-2288

Abstract Background: For newly diagnosed (ND) patients with multiple myeloma (MM), treatment selection is influenced by transplant eligibili...

Outcomes for female patients with multiple myeloma: A national retrospective trend analysis from 2015 to 2022

Danielle Thor, Tony Elias, Vineet Polineni et al. Nov 03, 2025 pp. 8119-8119 10.1182/blood-2025-8119

Abstract Introduction: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at...

Incidence and impact of acute coronary syndrome on outcomes in chimeric antigen receptor T-cell therapy: Insights from a six-year nationwide analysis

Adamsegd Gebremedhen, Abdu Mohammed, Mamdouh Souleymane et al. Nov 03, 2025 pp. 6330-6330 10.1182/blood-2025-6330

Abstract Introduction Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or ref...

Complete blood count monitoring for patients on anticoagulation with direct oral anticoagulants for atrial fibrillation and/or venous thromboembolism.

Jordan Schaefer, Josh Errickson, Xiaowen Kong et al. Nov 03, 2025 pp. 6246-6246 10.1182/blood-2025-6246

Abstract Introduction: Serial complete blood count (CBC) tests can identify potentially significant lab abnormalities for patients using the...

Do SSRIs increase bruising? a propensity-matched proxy analysis using generalized anxiety/depression

Bugra Zengin, Jasneet Randhawa, Zaid Zahid et al. Nov 03, 2025 pp. 6641-6641 10.1182/blood-2025-6641

Abstract Background: Selective serotonin reuptake inhibitors (SSRIs) are believed to increase bleeding risk by interfering with platelet fun...

A rare case of KIT-negative indolent systemic mastocytosis without anaphylaxis

Jackson Horn Nov 03, 2025 pp. 6562-6562 10.1182/blood-2025-6562

Abstract Introduction Mastocytosis is a clonal neoplastic disorder characterized by abnormal proliferation and accumulation of mast cells, m...

Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia: The mediating roles of relapse and salvage chemotherapy intensity

Quynh Long Khuong, Daniel Zheng, Gary Hettinger et al. Nov 03, 2025 pp. 5169-5169 10.1182/blood-2025-5169

Abstract Background Treatment for pediatric acute myeloid leukemia (AML) involves intensive anthracycline (ATC)-based chemotherapy, with car...

Transforming patient outcomes in multiple myeloma through real-time, text-based monitoring of symptoms (Sxs) and quality of life (QoL): Results from the mqol feasibility study

James Berenson, Regina Swift, Victor Tellez et al. Nov 03, 2025 pp. 406-406 10.1182/blood-2025-406

Abstract Background The dramatic improvement in the survival of multiple myeloma (MM) patients has led to an increased emphasis on their QoL...

CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy

Brian Betts, Constanza Savid-Frontera, Shannon McSain et al. Nov 03, 2025 pp. 4098-4098 10.1182/blood-2025-4098

Abstract Chimeric antigen receptor T cells (CAR T) targeting CD19 can cure approximately a third of patients with aggressive B cell malignan...

EPO treatment in combination with hydroxyurea improves pain and other quality of life measures in sickle cell disease

Kseniya Anishchenko, Nelly Kiriza, Feyisayo Oluwole et al. Nov 03, 2025 pp. 614-614 10.1182/blood-2025-614

Abstract Background: Anemia and pain are key features of sickle cell disease (SCD), leading to high morbidity and shorter life expectancy. P...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page